These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 33627824)

  • 1. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
    Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
    Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccinations: The unknowns, challenges, and hopes.
    Mohamed K; Rzymski P; Islam MS; Makuku R; Mushtaq A; Khan A; Ivanovska M; Makka SA; Hashem F; Marquez L; Cseprekal O; Filgueiras IS; Fonseca DLM; Mickael E; Ling I; Arero AG; Cuschieri S; Minakova K; Rodríguez-Román E; Abarikwu SO; Faten AB; Grancini G; Cabral-Marques O; Rezaei N
    J Med Virol; 2022 Apr; 94(4):1336-1349. PubMed ID: 34845731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccine trials must include helminth-infected cohorts.
    Egwang TG; Owalla TJ; Kemigisha M
    Nat Immunol; 2022 Feb; 23(2):148. PubMed ID: 35075281
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.
    Tran S; Truong TH; Narendran A
    Eur J Cancer; 2021 Dec; 159():259-274. PubMed ID: 34798454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad cross-national public support for accelerated COVID-19 vaccine trial designs.
    Broockman D; Kalla J; Guerrero A; Budolfson M; Eyal N; Jewell NP; Magalhaes M; Sekhon JS
    Vaccine; 2021 Jan; 39(2):309-316. PubMed ID: 33334616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).
    Body A; Ahern E; Lal L; Gillett K; Abdulla H; Opat S; O'Brien T; Downie P; Turville S; Munier CML; Smith C; MacIntyre CR; Segelov E
    BMC Infect Dis; 2022 Jan; 22(1):70. PubMed ID: 35057745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients.
    Mulhern JG; Fadia A; Patel R; Ficociello LH; Willetts J; Dahne-Steuber IA; Pollan MC; Mullon C; DeLisi J; Johnson C; Mysayphonh C; Kossmann RJ; Anger MS; Hymes JL
    Clin J Am Soc Nephrol; 2021 Nov; 16(11):1720-1722. PubMed ID: 34312162
    [No Abstract]   [Full Text] [Related]  

  • 9. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Vaccination Imperatives in People on Maintenance Dialysis: An International Perspective.
    Blake PG; Hladunewich MA; Oliver MJ
    Clin J Am Soc Nephrol; 2021 Nov; 16(11):1746-1748. PubMed ID: 34281983
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
    Malek AE; Cornejo PP; Daoud N; Alam M
    Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
    Hodgson SH; Mansatta K; Mallett G; Harris V; Emary KRW; Pollard AJ
    Lancet Infect Dis; 2021 Feb; 21(2):e26-e35. PubMed ID: 33125914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral and social science in support of SARS-CoV-2 vaccination: National Institutes of Health initiatives.
    Hunter CM; Chou WS; Webb Hooper M
    Transl Behav Med; 2021 Jul; 11(7):1354-1358. PubMed ID: 34080616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.